|Bid||0.00 x 1000|
|Ask||0.00 x 1400|
|Day's Range||64.94 - 66.53|
|52 Week Range||60.14 - 84.00|
|PE Ratio (TTM)||10.25|
|Earnings Date||Aug 8, 2018|
|Forward Dividend & Yield||2.00 (3.11%)|
|1y Target Est||86.80|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after Campbell Soup reported third quarter earnings that beat Wall Street expectations.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.
A habit of safe thinking has been sinking General Electric for years. Since John Flannery took the helm last June, GE(GE) at every turn has shown a preference for incremental solutions, avoiding risk and averting its gaze from the massive changes its businesses face. In 2017, when activist investors finally lost patience with Jeffrey Immelt, they replaced him with Flannery, the classic company man.
LabCorp CEO David King said the agreement is the result of a "years-long effort to return to a full collaborative relationship with Aetna."
The U.S. Department of Justice said on Thursday that the civil settlement resolves allegations that Pfizer improperly used the Patient Access Network Foundation as a conduit to cover co-payment obligations of patients taking three Pfizer drugs. Pfizer's actions enabled the New York-based drugmaker to boost prices and revenue, violating the federal False Claims Act in a scheme that ran from 2012 to 2016, the department said.
“There’s a huge problem where we optimize for beach days and forget about every other day,” said the CEO of Sundots, which infuses gummy candies with a fern extract that helps to protect skin cells against UV radiation.
Not only that, recent controversies can have a serious impact on Starbucks stock. Only a few days ago, Starbucks was forced to apologize when one of its Los Angeles-area stores committed racial discrimination against a Latino customer. On May 29, all Starbucks locations will close to attend this mandatory event.
CVS Health’s recent acquisition of Aetna has sparked talk of a pharmacy of the future, in which CVS’s walk-in “minute clinics” offer more services, and in a more accessible way than traditional health care. Bertolini, who has previously compared this goal to Apple’s (AAPL) Genius Bar, said CVS stores and services could become a “tent without walls,” by say, encouraging an individual with Type 1 diabetes named Sally to exercise a certain amount and keep her hemoglobin levels below a certain point.
The FDA released a list of drugmakers it said are getting in the way of generic drug development. Stocks of pharmacy benefit managers and biotech companies still outperformed the market. The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.
Signs abound that the Trump administration plans to take tough action against pharmacy benefit managers, or PBMs, including CVS Health Corp (NYSE:CVS) and Express Scripts Holding Company (NASDAQ:ESRX), in order to lower the price of prescription drugs. Consequently, investors should sell CVS stock and Express Scripts stock. The clearest sign of the impending fate of the PBMs is that President Trump himself said that the administration was “very much eliminating” the prescription drug “middlemen.” Trump added that “The middlemen became very, very rich.
In early January, Jeff Bezos of Amazon.com Inc. ( AMZN), Warren Buffett of Berkshire Hathaway Inc. ( BRK.A) and Jamie Dimon of JPMorgan Chase & Co. ( JPM) announced plans to develop a joint venture aimed at cutting the costs associated with U.S. health care. While that project may have been welcome news for some individual participants in the health system, it spelled trouble for health insurance companies.
CVS Health Corporation (NYSE:CVS) has pleased shareholders over the past 10 years, paying out an average dividend of 2.00% annually. The stock currently pays out a dividend yield of 3.02%,Read More...
The credit agency still has concerns about the company’s high debt levels.
As Rite Aid and Albertsons work through their merger, they are touting growth potential and the ability to compete with retailers Walmart, CVS Health, Walgreens Boots Alliance and grocer Kroger on a national level. Executives Tuesday said there is while tapping new markets for health and drug benefits, particularly for seniors insured by Medicare in California where both have strong brands. Combined, Albertsons and Rite Aid say the proposed new company will have $82 billion in sales, ranking fifth behind Walmart, which at No. 1 will be more than triple its size with more than $300 billion in annual revenue.
TripAdvisor (TRIP) reported its first-quarter results on May 10. Its revenue grew 1.6% to $378 million and surpassed the consensus estimate by 4.6%. It reported a drastic increase in earnings to $0.30 per share compared to EPS (earnings per share) of $0.24 in the first quarter of 2017. Its EPS also surpassed the consensus estimate of $0.16 per share. The stock rose 24.2% last week.
WASHINGTON/NEW YORK, May 14 (Reuters) - The Trump administration is considering expanding Medicare's ability to negotiate the cost of drugs by giving private payers a role in setting the price of medicines administered in hospitals and doctors' offices, Health and Human Services Secretary Alex Azar said on Monday. Azar's comments provided more details on the plan to lower prescription drug costs for Americans announced on Friday by President Donald Trump. While Trump assailed "middlemen," an apparent reference to health insurers and pharmacy benefit managers (PBMs), for pocketing negotiated rebates on drugs rather than passing savings to consumers, the proposal discussed on Monday appears to see them as part of the solution to high prices.
Managed-care organizations showed healthy upside in the first quarter, but the biggest story in MCO-land remains, of course, the upcoming CVS Health (CVS) acquisition of Aetna (AET). Credit Suisse analyst A.J. Rice in a Monday research report lowered his Aetna target to $194 from $208 but remains Neutral on the stock. "We use a 70% probability that the AET-CVS deal is approved ($197 deal price based on current CVS price).
On Friday, stocks digested the big rally over the past week, with many names trading in a rather tight range. That’s something we haven’t seen in a while, with markets more volatile in 2018 vs 2017. In any regard, here are the top stock trades we’re watching for this week.Top Stock Trades for Monday #1: Nvidia (NVDA)
When a firm's top brass regularly receives employee stock options they aren't prone to buy shares on the open market. Situations like that are almost always resolved when the stock "catches up" to the improvement in fundamentals.
Healthcare investors who were on the edges of their seats on Friday afternoon were relieved. Share prices of potentially-affected “middlemen” such as pharmacy-benefit managers, and to a lesser extent health insurers, fell sharply but then rebounded within minutes in late trading. After all, Mr. Trump’s comments were characteristically vague and didn’t unveil any immediate action to cut drug spending that might harm the profitability of companies like Express Scripts Holding or CVS Health.
WASHINGTON—President Donald Trump unveiled dozens of initiatives aimed at curbing high drug prices Friday, a raft of modest moves that left the pharmaceutical industry relieved and buoyed their stocks. “We’re going to take on one of the biggest obstacles to affordable medicine: the tangled web of special interests,” Mr. Trump said from the White House Rose Garden.
President Donald Trump this afternoon unveiled his plan to crack down on high-priced drugs. Pharmaceutical industry investors were unfazed. In fact, the stocks of the firms he hit hardest—the "middlemen" known as pharmacy-benefit managers—jumped as traders saw little in the administration's program that could hurt PBM outfits like Express Scripts Holding (ESRX) and CVS Health (CVS), the parent of the benefit business Caremark.